Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gait analysis sheds light on joint damage in moderate hemophilia

NCT ID NCT04024176

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers at Nantes University Hospital are studying how joint damage from bleeding affects walking in adults with moderate hemophilia. About 24 participants will have their gait measured with motion capture and force platforms during a single visit. The study also collects clinical, imaging, and blood data to build a full picture of joint health. The goal is to understand whether moderate hemophilia leads to subtle walking problems that standard care might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
quantified gait analysis
What this could lead to
If the study finds links between joint damage and walking problems, it could help doctors decide whether moderate hemophilia needs closer monitoring or earlier treatment.
What could go wrong
The study is small and observational, so it cannot prove cause and effect. It may not capture enough detail to change care, and results may not apply to children or people with severe hemophilia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Nov 2019

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have moderate Hemophilia A or B. * Have understood the protocol and signed its consent to participate. * Patient able to perform a walking test. * Patient affiliated to a social security system Exclusion Criteria: * Pregnant women * Minor * Majors under guardianship or curatorship * Refusal to participate; * Amputee of a lower limb * Need for technical walking assistance (walking sticks, walker,...). * Extensive dermatitis of the lower limbs (need for sensor installation for gait analysis); * Known NYHA (New York Heart Association) grade III or IV heart failure (resting dyspnea); * Unstable angina or myocardial infarction within three months of inclusion * Known severe respiratory disease; * Parkinson's disease, hemiplegia or paraplegia * Patient unable to understand the objectives or instructions of the study * Intercurrent pathology likely to modify walking abilities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthropathy moderately severe hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthropathy Moderate hemophilia

Contacts and locations

Locations

  • Department of Physical Medicine and Locomotive Rehabilitation (Nantes University Hospital)

    Nantes, France

  • Department of Physical Medicine and Neurological Rehabilitation (Nantes University Hospital)

    Nantes, France

  • Regional Hemophilia Treatment Centre (Nantes University Hospital)

    Nantes, France

  • Rheumatology department (Nantes University Hospital)

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.